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Abstract
Background: Untreated human immunodeficiency virus (HIV) disease disrupts B cell populations causing reduced
memory and reduced naïve resting B cells leading to increases in specific co-infections and impaired responses to
vaccines. To what extent antiretroviral treatment reverses these changes in an African population is uncertain.
Methods: A cross-sectional study was performed. We recruited HIV-uninfected and HIV-infected Malawian adults
both on and off antiretroviral therapy attending the Queen Elizabeth Central hospital in Malawi. Using flow
cytometry, we enumerated B cells and characterized memory B cells and compared these measurements by the
different recruitment groups.
Results: Overall 64 participants were recruited - 20 HIV uninfected (HIV-), 30 HIV infected ART naïve (HIV+N) and 14
HIV-infected ART treated (HIV+T). ART treatment had been taken for a median of 33 months (Range 12-60 months).
Compared to HIV- the HIV+N adults had low absolute number of naïve resting B cells (111 vs. 180 cells/μl p =
0.008); reduced memory B cells (27 vs. 51 cells/μl p = 0.0008). The HIV+T adults had B-cell numbers similar to HIV-
except for memory B cells that remained significantly lower (30 vs. 51 cells/μl p = 0.02). In the HIV+N group we did
not find an association between CD4 count and B cell numbers.
Conclusions: HIV infected Malawian adults have abnormal B-cell numbers. Individuals treated with ART show a
return to normal in B-cell numbers but a persistent deficit in the memory subset is noted. This has important
implications for long term susceptibility to co-infections and should be evaluated further in a larger cohort study.
Background
Untreated HIV infection leads to disruption of the
immune system leading to an increased risk of many
infections and in particular pneumococcal disease [1,2].
A classic feature of HIV-disease progression is the con-
sistent destruction of lymph nodes (LN) contributing to
the progressive loss of the CD4 T-cells and degeneration
of germinal centres. In addition there is massive and
progressive destruction of B cells as a consequence of
LN destruction and by a direct effect of HIV leading to
apoptosis of B cells [3,4]. This decline in the B cell
numbers is a major factor rendering HIV-infected indi-
viduals incapable of mounting an effective functional
antibody response to pneumococcal polysaccharides [5]
In addition to increased immunoglobulin secretion
and a decrease in number of naïve resting B cells [6],
HIV leads to multiple measurable defects in the B-cell
subpopulations. Previous reports have shown reduced
numbers of circulating CD19+CD27+ memory B cells
both in adult and paediatric groups [7,8]. HIV also leads
to B cell hyperactivation which is characterized by
increased expression of activation markers [9,10], poor
expression of CD19+CD21+ (naive mature B cells) on
peripheral B cells [11] and have increased frequency of
immature transitional B cells (CD10+CD21lowCD27-) in
the peripheral blood [12].
It is now becoming clear that many of these B cell
defects associated with HIV are reversed by anti retro-
viral therapy (ART) with the exception of memory B
cells which remain low despite control of HIV load
[13-16]. However despite these advances in our under-
standing of B cell defects associated with HIV and their
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reverse caused by ART, very few studies looking at these
B cell abnormalities in HIV have been conducted in
Africa. Ethnic origin and thus genetic background of
individuals, different clades of the HIV virus, altered
clinical presentation, different co-infections, and limited
or delayed access to health care may result in different
outcomes compared to studies from developed coun-
tries. Only one study pre ART conducted in Central
Africa where they characterised peripheral B cell com-
partments in HIV infected individuals and observed
germinal center B cells in blood has been conducted so
far [17]. Treatment with antiretroviral therapy is
improving the outcome of HIV-infected Africans. How-
ever they remain at increased risk for many opportunis-
tic infections including pneumococcal disease. How far
the immune system reconstitutes and to what extent B-
cell defects return to normal is important for under-
standing whether and how vaccines for pneumococcal
disease control can be used. There is limited data on
the extent to which B-cell characteristics revert back to
normal takes place in Africa.
We have measured B cell numbers and memory B
cells numbers and relative percentages in adults in Blan-
tyre, Malawi to see how far previously described HIV-
associated abnormalities are present in our population
of adults and how these abnormalities are changed after
anti-retroviral therapy. This work was undertaken as
part of a wider investigation of the cellular response to
pneumococcal polysaccharides, results of which will be
reported separately.
Methods
Study participants
Participants for the study were identified through the
Wellcome Trust adult clinical research clinic at Queen
Elizabeth Central Hospital (QECH) in Blantyre. The
study aimed to recruit a total of 60 adult participants in
5 groups: 20 HIV-uninfected; 10 HIV-infected with CD4
> 200 cells/mm3; 10 HIV-infected with CD4 ≤ 200 cells/
mm3;10 HIV-infected adults on ART treatment for
more than one year; and 10 HIV-infected adults conva-
lescing from an invasive pneumococcal (IPD) event. Par-
ticipants were recruited into a study investigating
pneumococcal polysaccharide directed B-cell responses
and no formal sample size calculation was undertaken.
With the exception of the IPD cases, participants were
recruited after volunteering following a public advertise-
ment in the hospital. Individuals recovering from pneu-
mococcal disease were identified from blood culture
records and approached by a study team member for
consent. Study participants underwent a structured clin-
ical assessment and then provided 5 mls of blood in
EDTA for phenotypic analysis. HIV-infected participants
found to have low CD4 counts and not on ART were
counselled and encouraged to attend the ART clinic.
All participants gave signed informed consent before
recruitment. The study was approved by the College of
Medicine Research and Ethics Committee, Malawi
under protocol number P 99/00/101.
Blood specimen
Blood samples were processed within two hours of col-
lection. CD4+ T cell count and full blood count to
determine the absolute lymphocyte count and the white
cell count were performed on a FACSCount™ system
(Becton Dickinson, San Jose, California, USA) and a
Coulter® HmX haematology analyser (Beckman Coulter
™ Company, Miami Florida, USA) respectively.
B cell Immunophenotyping
The absolute counts and the relative percentages of B
cells and memory B cell subpopulation (CD27+) were
investigated. The B cells and memory B cell subset were
stained with the following monoclonal antibodies conju-
gated with fluorescein isothiocyanate (FITC), phycoery-
thrin (PE), and allophycocyanin (APC) suitable for
three-colour flow cytometry. The following phenotypic
markers were used: CD19-FITC, CD19-PE, CD19-APC
(B cell markers), CD45-FITC, CD45-APC (leukocyte
markers) CD3-APC (T cell marker), CD27-PE (memory
B cell maker), (All from Becton Dickinson Biosciences,
San Jose, CA). Immunoglobulin isotype-matched FITC-,
PE-, APC-conjugated monoclonal antibodies (Becton
Dickinson Biosciences, San Jose, CA) were used as nega-
tive controls to check for non specific staining. Briefly,
the red blood cells were lysed for 20 minutes using BD
lyse solution (Becton Dickinson Biosciences, San Jose
California, USA). The cells were washed twice with 1%
faetal calf serum (FCS) in phosphate buffered saline
(PBS). In between washes the cells were blocked for 15
minutes with 2 ml PBS/1%FSC/5 μg human polyclonal
IgG (Sigma)/10 μl mouse polyclonal IgG (Caltag)/50 μl
Immune human serum. The white blood cells were
stained with the appropriate monoclonal antibody for 30
minutes in the dark. Afterwards, the cells were washed
in PBS containing 1% foetal calf serum and fixed in 2%
paraformaldehyde before analysis. The B cell subsets
were analysed on FACSCalibur flow cytometer (Becton
Dickinson Immunocytometry Systems, San Jose Califor-
nia, USA) with CellQuest-Pro™ software (Becton Dickin-
son, San Jose California, USA) used for analysis.
Lymphocytes were gated on forward and side scatter and
50, 000 events were gathered. CD19+ B cells were expressed
as a percentage of the total lymphocyte count and as the
absolute count of CD19+ lymphocytes per 1000 μL blood.
Memory B cells were defined as CD19+CD27+ B cells.
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Statistical analysis
For statistical analysis, study participants were divided
into three primary groups: HIV negative (HIV-), HIV
positive ART naïve (HIV+N) and HIV positive on ART
(HIV+T). Within the HIV+N, three secondary groups
were also analysed namely: HIV positive with low CD4
T cell counts, HIV positive with high CD4 T cell counts
and IPD cases. The data were not normally distributed
(Shapiro-Wilk normality test) and two-way comparisons
between the study groups were analysed by Mann-Whit-
ney U test. Correlation between absolute B cell counts
and CD4 counts in HIV positive adults ART naive and
on ART was performed by Spearman’s rank correlation
test. The median and ranges (minimum and maximum)
are used as summary statistics within the text and in the
tables. P values of less than 0.05 were considered
significant.
Results
A total of 64 participants were recruited to the study
(47% male): 20 HIV-, 30 HIV+N and 14 HIV+T. Demo-
graphic and clinical characteristics of the study partici-
pants are summarised in Table 1. All the IPD cases
were HIV positive. There were more women in the HIV
+T group than the other groups and age did not differ
significantly between all the study groups (Table 1). In
the HIV+T group the CD4+ T cells count increased sig-
nificantly after a mean period of 33 months of ART (p <
0.0001) but remained significantly less than the HIV-
group (p = 0.006). Results of the memory B cell subset
based on cell counts were similar to those based on per-
centages. Absolute counts of total B cells and memory
B cell subset are thus presented in table 2.
Absolute B cell counts
Compared to HIV- participants-the absolute number of
B cells (Figure 1) were significantly reduced in HIV+N
participants (111 vs. 180 cells/μl, p = 0.008). The abso-
lute B cell count was also reduced in HIV+T partici-
pants but the difference was not significant (128 cell/μl,
p = 0.52). There were no significant differences in the
median B cell counts between the HIV+N subgroups
(Table 2).
CD4 T cell counts and B cell counts in HIV-infected adults
Overall there was no significant association between
CD4 T-cell count and absolute B-cell counts in the trea-
ted and non treated subgroups. However, there was a
tendency to a direct association between CD4 T cell
counts and absolute B cell counts, Figure 2b, in HIV
+T group, (rho = 0.5, p = 0.07) but not in the HIV +N
participants, Figure 2a (rho = 0.2, p = 0.31).
Change in absolute counts and percentages of memory
B cells
Compared to HIV- participants, HIV+N participants had
lower absolute counts of memory B cells (p = 0.0008).
Similar results were also obtained for percentages of
memory B cells (p = 0.049).
The absolute counts and percentage of the memory
B cells remained low in HIV+T participants compared
to HIV- participants (p = 0.02 and p = 0.005 respec-
tively). There were no significant differences in the abso-
lute counts and percentages of the memory B cells
between the HIV+N subgroups.
Discussion
In this small cross-sectional study, we have shown that
HIV infected adults have significant reduction of total
B cell numbers and memory B cells. Following ART B
cell numbers are similar to HIV-uninfected adults but
there are persisting defects in the memory B cell
subset.
B cell numbers have been reported to be reduced dur-
ing HIV infection as a result of B cell apoptosis trig-
gered by HIV gp120 leading to B cell activation during
infection [18]. As expected, it was observed that B cell
numbers are significantly reduced in HIV positive adults
ART naive. The counts were higher in patients on ART.
These results are similar to previous report [14] which
showed B cell numbers to improve with reduction of
HIV viremia as a result of ART.
Table 1 Demographic and clinical characteristics of study participants, by HIV infection status, ART and IPD event
Variable Study group
HIV Negative
(n = 20)
HIV+ CD4 < 200
(n = 10)
HIV+ CD4≥200
(n = 10)
HIV+ on ART
(n = 14)
IPD cases
(n = 10)
Age, mean years (SD)* 34.3 (10.4] 33 (6.2) 29.1 (6.0) 42.9 (10.7) 37.2 (10.4)
Sex, female percentage 35 30 60 79 30
CD4+ T cell count at sampling, median [range] 784 [334-1122] 117 [37-196] 450 [335-574] 349 [166-838] 223 [40-558]
CD4+ T cell count pre-ART, median [range] - - - 138 [20-180] -
Period on ART, mean months - - - 33 -
Total lymphocyte count, median [range] 1850 [800-3000] 1400 [800-1800] 1500 [1100-2600] 2050 [1000-3800] 1350 [600-2300]
*Age was not statistically significantly different between the study groups.
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Memory B cells are identified by CD27 marker on the
surface of the cells [19] Evaluation of memory B cells is
important in determining the capacity of the immune
system in producing functional and class-switched anti-
bodies. Our findings are similar to previous studies that
reported total memory B cells to be reduced (in both
proportional and absolute terms) in untreated HIV
infected adults [7-9,20]. A similar study which recruited
African individuals also showed reduced memory B cells
in HIV infected ART naïve patients [17]. Previous
reports [21]showed that increased risk of pneumococcal
disease in untreated HIV positive patients might partly
be a consequence of depleted absolute memory B cell
counts. No significant difference in the absolute memory
B cell counts was detected in the IPD cases compared to
HIV infected adults without IPD.
Both percentage and absolute numbers of the memory
B cells did not increase in HIV positive adults on ART
(mean of 33 months on ART) and were actually lower
than in the ART naive HIV positive adults. These data
are consistent with findings reported by De Milito et al.
who suggested that loss of memory B cells might occur
early after infection and may not be corrected by ther-
apy. Recently a similar study that looked at activated
and resting memory B cells in HIV infected individuals
on ART showed an increase in numbers of resting
memory B cells and a reduction in activated memory
B cells [14]. However in the present study, no distinc-
tion was made between resting and activated memory
B cells. A possible explanation to low numbers of mem-
ory B cells in HIV infected individuals could be that
there were more activated memory B cells than resting
memory B cells. However this needs to be further inves-
tigated. Some reports show ART to have no effect on
susceptibility of HIV patients to IPD [21]. Our findings
would be consistent with this clinical finding and may
provide a partial explanation for it.
The study showed no relationship between CD4 T-cell
count and B-cell numbers although in the treated HIV
positive adults there appeared to be a tendency to a
direct association. The failure to see an overall associa-
tion may be a consequence of small study numbers.
Plasma viral load, which we did not measure, may also
be an important determinant of B-cell numbers and
may confound any association, except in the case of the
ART treated group when viral suppression allows the
true relationship between B-cells and CD4 T-cells to
become apparent.
The study has a number of limitations. The sample
size was small, forming part of a more detailed study of
antigen-specific B-cell characteristics. Selection of
patients was not random and relied on volunteers
responding to a public announcement. The units well
known association with respiratory disease research may
have inadvertently biased recruitment in favour of indi-
viduals with previous concerns about respiratory health
and perhaps a population biased towards abnormal
B-cell function. Nevertheless, the study points to an
Table 2 Absolute counts (x103cells/ml) of B cells and memory B cells from study participants by HIV infection status,
ART and IPD cases
Study group
HIV negative HIV positive
ART naive On ART
Variable CD4 < 200 CD4≥200 IPD All P1 P2
Absolute B cell count, median [range] 180.2 [70-427.5] 128.7 [48-208] 85.5 [46.8-196] 109.5 [45-230] 111.2 [45-230] 0.008 128 [20.8-445] 0.52
Absolute
CD27+ B cell count, median [range]
51 [20.8-129.5] 31.8 [10.3-76] 20.2 [10-62.2] 28.5 [5.4-60.3] 27 [5.4-76] 0.0008 30.3 [5.6-108] 0.02
P1: p value comparing all HIV positive (ART naïve) with HIV negative group. P2: p value comparing HIV positive on ART with HIV negative group.
Figure 1 Absolute B cell counts from HIV negative, HIV
positive ART naïve and on ART. Medians (10th and 90th
percentiles) of absolute B cell counts (x103cells/ml) in HIV negative
(n = 20), HIV infected subjects ART naïve (n = 30) and HIV infected
subjects on ART (n = 14).
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important failure in recovering memory B-cell subsets
and a larger study is now justified, to measure the size
of this problem. Viral load measurements were not
made and thus we cannot conclude that the investigated
participants were receiving successful suppressive ART,
although all were clinically well at the time of
enrolment. A prospective cohort study is now planned
to investigate these findings further.
Conclusions
The study has shown that HIV-infected Malawian adults
have significant quantitative defects in B cell numbers
Figure 2 Scatter plots evaluating correlation between CD4 T cell and absolute B cell counts and between absolute B cell counts and
total lymphocyte counts in both HIV+N and HIV+T. Scatter plots evaluating correlation between CD4 T cell counts and absolute B cell
counts in HIV positive adults ART naïve (Figure 2a) and HIV positive adults on ART (Figure 2b). Correlation between absolute B cell counts and
total lymphocyte counts in HIV positive adults ART naïve (Figure 2c) and HIV positive adults on ART (Figure 2d)
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and memory B cells. ART use is associated with normal-
isation of these defects but a persistent deficiency in the
memory subset appears to be retained. This has impor-
tant implications for long term susceptibility to co-infec-
tions and co-infection prophylaxis. Our findings are
limited by the small size and cross-sectional nature and
need to be evaluated further in a larger cohort study
specifically designed for this purpose.
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